psychedelics
3 Ways to Invest in Ketamine Clinics
Researchers believe that psychedelics may revolutionize mental health treatments, but FDA-approved psychedelics remain out of reach—with one exception. Unlike psilocybin or MDMA, ketamine is FDA-approved for anesthesia during medical procedures, opening the door to off-label use as a treatment for depression and other mental illnesses. With the FDA’s approval of Spravato and a growing body […]
Silo Wellness Appoints CEO Douglas K. Gordon to Board of Directors and Provides Corporation Updates
Toronto, Ontario–(Newsfile Corp. – January 6, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that the Company’s Chief Executive Officer, Douglas K. Gordon, has been appointed as a director of the company. Mr. Gordon has led the company […]
Entheon Biomedical Announces EEG Patent Application & Provides Research Update
Vancouver, British Columbia–(Newsfile Corp. – December 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as […]
MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer
VANCOUVER, BC, Dec. 14, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”). Dr. Joel Raskin who was acting CMO will transition into an advisory role […]
Revitalist Executes on Vision to Become a Clinical Leader in Psychedelics
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms, with more […]
Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with Acquired Immune Deficiency Syndrome (AIDS) 83,000 […]
VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“N,N-Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services. […]
TAMPA, FLA. (PRWEB) DECEMBER 07, 2021 Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of psychedelic compounds and outpatient delivery methods for the treatment of anxiety, substance abuse, and PTSD, is thrilled to receive positive results from in vivo preclinical studies. A modified DMT derivative, PSIL-002, was safe, well-tolerated, and without hallucinogenic effects at all […]
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway Vancouver, British Columbia–(November 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on […]
TORONTO–(BUSINESS WIRE)-11/23/2021- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York. The […]
Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights
FDA Authorization of Historic Phase I Clinical Trial Using All-Natural Psychedelic Compounds and Direct Psilocin Administration for the First Time Granted First and Only Patent for Extraction and Standardization of Natural Psilocybin Health Canada Dealer’s License Enables Production and Distribution of All Natural cGMP-Grade Psychedelic Supply from its Facilities VANCOUVER, BC, Nov. […]
Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets
Vancouver, British Columbia–(Newsfile Corp. – November 15, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) (“Lobe” or the “Company“) today announced that its common stock ticker will change from “GTSIF” to “LOBEF” and will commence trading under the symbol “LOBEF” in US markets at the opening of the market on November 15, 2021 […]
Nutritional High Renames Psychedelic Subsidiary and Appoints Ian Campbell as CEO
Toronto, Ontario–(Newsfile Corp. – November 10, 2021) – Nutritional High International Inc. (CSE: EAT) (“Nutritional High” or the “Company“) is pleased to announce the name change of its wholly-owned subsidiary Psychedelic Science Corp., which it acquired in August 2020 (please see the press releases dated August 17, 2020 and February 10, 2021) and appointment of Ian Campbell as […]
Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet, despite significant investment in clinical trials, the FDA has only approved two types of […]
BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies
VANCOUVER, British Columbia, Sept. 29, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has obtained its first set of neurological receptor binding […]
Delic Announces Partnership with GT Research
Co-Marketing Agreement to Offer Computational Genetic Analysis and Trait Optimization for Cannabis and Psychedelics VANCOUVER, BC, Oct. 26, 2021 /CNW/ – Delic Holding Corp Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Delic Labs, has entered into a […]
Building the DoorDash or UberEats of Psychedelics
The psychedelics industry is rapidly growing, with more than 50 publicly traded companies worth billions of dollars. At the same time, the FDA’s approval of Spravato (esketamine) for treatment-resistant depression and the growing body of clinical evidence could provide further tailwinds for the industry over the coming decade and beyond. Unfortunately, many patients live in […]
TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that it has filed a provisional patent application (PPA) with the United […]
Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1
Toronto, Ontario–(Newsfile Corp. – October 7, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that KGK Science, a licensed contract research organization (CRO) in Canada, is commencing the next pre-clinical trial […]
VANCOUVER, BC, Oct. 6, 2021 /PRNewswire/ – Clairvoyant Therapeutics (“Clairvoyant”), a Canadian biotech company focused on the development of psychedelic drug therapies for addiction, is pleased to announce Greg Engel has joined the company’s Board of Directors and Long Trinh has joined as Chief Financial Officer (CFO). Mr. Engel has more than 25 years of global leadership experience in the pharmaceutical, […]
Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience Vancouver, British Columbia–(Newsfile Corp. – October 6, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Krysalis VX Innovations Inc. (“Krysalis”), the Virtual experience (“VX”)-focused company designing […]
Silo Pharma Looks to Become a NASDAQ Biotech
Silo Pharma Inc. (OTCQB: SILO) is a cutting-edge, development-stage biotechnology company focused on merging traditional therapeutics with emerging psychedelic research for people suffering from indicators such as depression, post-traumatic stress disorder, Parkinson’s disease, and other rare neurological disorders, representing billion-dollar markets. The company submitted an initial application to list on the NASDAQ Capital Market—a move […]
TORONTO, October 01, 2021–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company“), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as its new Head of Research & Development, the promotion […]
TORONTO, September 28, 2021–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company“) (NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. “With this seventh patent application, governed by the Patent Cooperation Treaty, […]
Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ – Lobe Sciences Ltd. (“Lobe” or the “Company“) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in […]
Toronto, Ontario–(Newsfile Corp. – September 27, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an agreement to fund a second research and development […]
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Company has been included to the North American Psychedelics Index, (the “Index”), which is the underlying index of the Horizons Psychedelic Stock Index Exchange Traded Fund […]
Enveric Biosciences Announces Closing of MagicMed Industries Acquisition
Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress NAPLES, Fla., Sept. 17, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing of its acquisition of MagicMed Industries Inc. (“MagicMed”), a […]
Lobe Sciences Provides Corporate Update to Investors and Stakeholders
Vancouver, British Columbia–(Newsfile Corp. – September 13, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company: Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts, We are pleased to say […]
Novamind Uplists to OTCQB Venture Market
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that, effective today, its common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market (the “OTCQB”), a U.S. trading platform operated […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Ehave, Inc. (EHVVF) is a leader in digital therapeutics delivering evidence-based therapeutic interventions to patients.
Next Green Wave is a fully integrated premium seed to shelf craft cannabis producer offering products through its in-house brand portfolio and wholesale flower for other large cannabis manufacturers.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
